ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LOH: reductio ad absurdum of the cardiovascular risk–benefit of TRT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 183478" data-attributes="member: 13851"><p><strong>Late-onset hypogonadism: <span style="color: rgb(184, 49, 47)">reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy </span></strong></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Abstract</strong></span></p><p></p><p><strong>Background: </strong><em><span style="color: rgb(184, 49, 47)">Low testosterone (T) level is considered a marker of poor cardiovascular health.</span></em> Ten years ago, the Testosterone in Older Men with Mobility Limitations (TOM) trial was discontinued due to a higher number of adverse events in men receiving T compared with placebo. Since then, several studies have investigated the risks of T replacement therapy (TRT) in late-onset hypogonadism (LOH).</p><p></p><p><strong>Objective:</strong> <em><span style="color: rgb(184, 49, 47)">To review the mechanism by which TRT could damage the cardiovascular system </span></em></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Materials and methods:</strong></span> Comprehensive literature search of recent clinical and experimental studies</p><p></p><p><strong>Results:</strong> The mechanisms of T-mediated coronary vasodilation were reviewed with emphasis on calcium-activated and ATP-sensitive potassium ion channels. We showed how T regulates endothelial nitric oxide synthase (eNOS) and phosphoinositide 3-kinase/protein kinase B/eNOS signaling pathways in vessel walls and its direct effects on cardiomyocytes via β1-adrenergic and ryanodine receptors and provided data on myocardial infarction and heart failure. Vascular smooth muscle senescence could be explained by the modulation of growth factors, matrix metalloproteinase-2, and angiotensin II by T. Furthermore, leukocyte trafficking, facilitated by changes in TNF-α, could explain some of the effects of T on atheromatous plaques. Conflicting data on prothrombotic risk linked to platelet aggregation inhibition via NO-triggered arachidonate synthesis or increased aggregability due to enhanced thromboxane A in human platelets provide evidence regarding the hypotheses on plaque maturation and rupture risk. The effects of T on cardiac electrophysiology and oxygen delivery were also reviewed.</p><p></p><p><strong>Discussion:</strong> <em><span style="color: rgb(184, 49, 47)">The effects of TRT on the cardiovascular system are complex.</span></em> Although molecular studies suggest a potential benefit, several clinical observations reveal neutral or occasionally detrimental effects, mostly due to confounding factors.</p><p></p><p><strong>Conclusions: </strong>Attempts to demonstrate that TRT damages the cardiovascular system via systematic analysis of the putative mechanisms led to the contradiction of the initial hypothesis. <em><span style="color: rgb(184, 49, 47)">Current evidence indicates that TRT is safe once other comorbidities are addressed. </span></em></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion</strong></p><p></p><p><em><span style="color: rgb(44, 130, 201)"><strong>Using the reductio ad absurdum logic, we contradicted the initial assumption of an overall harmful effect of T on the CV system. Although T has been demonstrated to have overall favorable effects on vasomotion, arterial stiffness, atherosclerosis, cardiac electrophysiology, oxygen delivery, cardiac contractility, and remodeling, </strong></span><span style="color: rgb(184, 49, 47)"><strong>it possesses a prothrombotic effect due to its action on platelet function and blood viscosity</strong>.</span></em> <span style="color: rgb(44, 130, 201)"><strong><em>In summary, based on the current evidence, CV disease does not appear to be increased in patients undergoing TRT.178,179</em></strong></span> <span style="color: rgb(184, 49, 47)"><strong><em>Most physicians against TRT will argue that TRT is “neutral” in terms of CV safety. While the latter is possible, the indication for TRT has never been to address CV dysfunction but rather to improve various signs and symptoms in LOH that correlate well with low testosterone levels. Nonetheless, in older patients with a known CV risk factor, a tailored approach is suggested.14,25 Symptoms, comorbidities, baseline and target levels of T, formulation, and therapy timing25,180,181 should be considered to improve sexual function, mood, depressive symptoms, and the mobility of patients with low testosterone levels.13,33,182,183</em></strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 183478, member: 13851"] [B]Late-onset hypogonadism: [COLOR=rgb(184, 49, 47)]reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy [/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]Abstract[/B][/COLOR] [B]Background: [/B][I][COLOR=rgb(184, 49, 47)]Low testosterone (T) level is considered a marker of poor cardiovascular health.[/COLOR][/I] Ten years ago, the Testosterone in Older Men with Mobility Limitations (TOM) trial was discontinued due to a higher number of adverse events in men receiving T compared with placebo. Since then, several studies have investigated the risks of T replacement therapy (TRT) in late-onset hypogonadism (LOH). [B]Objective:[/B] [I][COLOR=rgb(184, 49, 47)]To review the mechanism by which TRT could damage the cardiovascular system [/COLOR][/I] [COLOR=rgb(0, 0, 0)][B]Materials and methods:[/B][/COLOR] Comprehensive literature search of recent clinical and experimental studies [B]Results:[/B] The mechanisms of T-mediated coronary vasodilation were reviewed with emphasis on calcium-activated and ATP-sensitive potassium ion channels. We showed how T regulates endothelial nitric oxide synthase (eNOS) and phosphoinositide 3-kinase/protein kinase B/eNOS signaling pathways in vessel walls and its direct effects on cardiomyocytes via β1-adrenergic and ryanodine receptors and provided data on myocardial infarction and heart failure. Vascular smooth muscle senescence could be explained by the modulation of growth factors, matrix metalloproteinase-2, and angiotensin II by T. Furthermore, leukocyte trafficking, facilitated by changes in TNF-α, could explain some of the effects of T on atheromatous plaques. Conflicting data on prothrombotic risk linked to platelet aggregation inhibition via NO-triggered arachidonate synthesis or increased aggregability due to enhanced thromboxane A in human platelets provide evidence regarding the hypotheses on plaque maturation and rupture risk. The effects of T on cardiac electrophysiology and oxygen delivery were also reviewed. [B]Discussion:[/B] [I][COLOR=rgb(184, 49, 47)]The effects of TRT on the cardiovascular system are complex.[/COLOR][/I] Although molecular studies suggest a potential benefit, several clinical observations reveal neutral or occasionally detrimental effects, mostly due to confounding factors. [B]Conclusions: [/B]Attempts to demonstrate that TRT damages the cardiovascular system via systematic analysis of the putative mechanisms led to the contradiction of the initial hypothesis. [I][COLOR=rgb(184, 49, 47)]Current evidence indicates that TRT is safe once other comorbidities are addressed. [/COLOR][/I] [B]Conclusion[/B] [I][COLOR=rgb(44, 130, 201)][B]Using the reductio ad absurdum logic, we contradicted the initial assumption of an overall harmful effect of T on the CV system. Although T has been demonstrated to have overall favorable effects on vasomotion, arterial stiffness, atherosclerosis, cardiac electrophysiology, oxygen delivery, cardiac contractility, and remodeling, [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]it possesses a prothrombotic effect due to its action on platelet function and blood viscosity[/B].[/COLOR][/I] [COLOR=rgb(44, 130, 201)][B][I]In summary, based on the current evidence, CV disease does not appear to be increased in patients undergoing TRT.178,179[/I][/B][/COLOR] [COLOR=rgb(184, 49, 47)][B][I]Most physicians against TRT will argue that TRT is “neutral” in terms of CV safety. While the latter is possible, the indication for TRT has never been to address CV dysfunction but rather to improve various signs and symptoms in LOH that correlate well with low testosterone levels. Nonetheless, in older patients with a known CV risk factor, a tailored approach is suggested.14,25 Symptoms, comorbidities, baseline and target levels of T, formulation, and therapy timing25,180,181 should be considered to improve sexual function, mood, depressive symptoms, and the mobility of patients with low testosterone levels.13,33,182,183[/I][/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LOH: reductio ad absurdum of the cardiovascular risk–benefit of TRT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top